Skip to main content

Table 2 Target volume and dose concept depending upon stage, grading and PSA

From: Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer – a phase I study

Low risk: white Medium risk: light grey High risk: dark grey  
Stage ≤ cT2a ≤ cT2c cT3
PSA ≤ 10 < 20 < 20
G 1 Gleason 2–3 Prostate Prostate & base of seminal vesicles 70 Gy Prostate & base of seminal vesicles & visible tumour 74 Gy
G 2 Gleason 4–6 Prostate Prostate & base of seminal vesicles 70 Gy Prostate & base of seminal vesicles & visible tumour 74 Gy
G 3 Gleason > 6 Prostate & base of seminal vesicles 70 Gy Prostate & base of seminal vesicles 70 Gy Prostate & base of seminal vesicles & visible tumour 74 Gy